CREZET

CREZET
Product Description

1) Indication :  Treatment of primary hypercholesterolemia or to decrease elevated fat level in blood (mixed hyperlipidemia) in adult patients 
2) Composition : Ezetimibe, Rosuvastain calcium (strength: 10/20mg, 10/10mg,10/5mg)
3) Dosage & Administration : Once a day with or without meal 
4) Development Plan :  Completed Clinical Phase III in Korea

We are actively seeking an overseas partner who is interested to run clinical development , registering and commercializing Crezet outside Korea.

Read more Show less

Daewoong Pharmaceutical Co.,Ltd

  • KR
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Cardiovascular Health
  • Model
    Fixed Dose Combination
  • Supplied from
    Korea, Republic Of
More specifications Fewer specifications
Sales Markets
Show more Show less

Daewoong Pharmaceutical Co.,Ltd

  • KR
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Daewoong Pharmaceutical Co.,Ltd (4)

  • NABOTA®

    Product NABOTA®

    Botulinum toxin type A  
    Indication: Glabella Lines (Approved in KR, US, CA, EU), Post Stroke Upper Limb Spasticity, Crow's feet, Blepharospasm, Benign Masseteric Hypertrophy (Approved in KR)
    - Nabota is the only 900kDa Neurotoxin approved in the US and EU since Botox.- It has demonstra...
  • ENVLO®

    Product ENVLO®

    Envlo (Enavogliflozin) is a best-in-class SGLT2 inhibitor for T2DM. 
    Highlights of Envlo are: 
    * Launched in Korea from May 2023
    * Approved by Korea MFDS in 2022 for T2DM 
    * T2DM Phase III was completed in Korea as a monotherapy and in combinations with other anti-diabetics (du...
  • Eposis

    Product Eposis

    2000, 3000, 4000, 5000, 6000, 8000, 10000IU / Pre-filled syringe Inj.

    rhEPO (recombinant human erythropoietin)

    Indication:
    Anemia in chronic renal failure

    - EposisTM demonstrated significant improvement and safety for patients with anemia in Chronic Renal Failure (CRF).
    ...
  • FEXUCLUE®

    Product FEXUCLUE®

    Fexuclue (Fexuprazan) is the best-in-class novel anti acid secretion agent with rapid onset time and potent acid suppressive effect, addressing the growing unmet needs of PPIs

    Highlights of Fexuclue are: * Launched in Korea (2022) and Philippines (2023)
    * Approved in Chile and Ecuador qq...

Daewoong Pharmaceutical Co.,Ltd resources (1)

  • DAEWOONG PR VIDEO (EN)

    Video DAEWOONG PR VIDEO (EN)

    We continue to take the initiative by making bold challenges and investments in R&D to leap forward as a global healthcare group. Following the 2022 launch of Fexuclue, a drug treating gastroesophageal reflux disease, the company released Envlo, a Type 2 diabetes treatment. By bolstering its R&D pipeline, Daewoong Pharmaceutical is developing first-in-class and best-in-class drugs.
    2023-07-27